
|Videos|September 6, 2017
Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.
Advertisement
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.
The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.
The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5



































